Does continued alendronate therapy improve bone mineral density and reduce fracture risk in postmenopausal women?

被引：2
|
作者：
Kraenzlin, Marius E. [1 ]
Meier, Christian [1 ]
机构：
[1] Univ Basel Hosp, Div Endocrinol Diabet Clin Nutr, CH-4055 Basel, Switzerland
来源：
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM | 2007年 / 3卷 / 10期
关键词：
alendronate; BMD; bone turnover; nonvertebral fracture; vertebral fracture;
D O I：
10.1038/ncpendmet0618
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：686 / 687
页数：2
相关论文
共 50 条
  • [31] Oral alendronate increases bone mineral density and reduces vertebral fracture incidence in postmenopausal osteoporosis
    Meunier, PJ
    BRITISH JOURNAL OF RHEUMATOLOGY, 1997, 36 : 15 - 19
  • [32] Bone mineral density and breast cancer risk in postmenopausal women
    Buist, DSM
    LaCroix, AZ
    Barlow, WE
    White, E
    Weiss, NS
    JOURNAL OF CLINICAL EPIDEMIOLOGY, 2001, 54 (04) : 417 - 422
  • [33] Bone mineral density and risk of breast cancer in postmenopausal women
    Qu, Xinhua
    Zhang, Xiaoyu
    Qin, An
    Liu, Guangwang
    Zhai, Zanjing
    Hao, Yongqiang
    Li, Huiwu
    Zhu, Zhenan
    Dai, Kerong
    BREAST CANCER RESEARCH AND TREATMENT, 2013, 138 (01) : 261 - 271
  • [34] Bone mineral density and risk of breast cancer in postmenopausal women
    Xinhua Qu
    Xiaoyu Zhang
    An Qin
    Guangwang Liu
    Zanjing Zhai
    Yongqiang Hao
    Huiwu Li
    Zhenan Zhu
    Kerong Dai
    Breast Cancer Research and Treatment, 2013, 138 : 261 - 271
  • [35] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Aysegul Atmaca
    Olcay Gedik
    Advances in Therapy, 2006, 23 : 842 - 853
  • [36] Effects of alendronate and risedronate on bone mineral density and bone turnover markers in late postmenopausal women with osteoporosis
    Atmaca, Aysegul
    Gedlik, Olcay
    ADVANCES IN THERAPY, 2006, 23 (06) : 842 - 853
  • [37] Comparison of Bone and Total Alkaline Phosphatase and Bone Mineral Density in Postmenopausal Osteoporotic Women Treated with Alendronate
    N. B. Watts
    D. K. Jenkins
    J. M. Visor
    D. C. Casal
    P. Geusens
    Osteoporosis International, 2001, 12 : 279 - 288
  • [38] Comparison of bone and total alkaline phosphatase and bone mineral density in postmenopausal osteoporotic women treated with alendronate
    Watts, NB
    Jenkins, DK
    Visor, JM
    Casal, DC
    Geusens, P
    OSTEOPOROSIS INTERNATIONAL, 2001, 12 (04) : 279 - 288
  • [39] ASSESSMENT OF BONE MINERAL DENSITY AND BONE TURNOVER MARKERS IN POSTMENOPAUSAL WOMEN TRANSITIONED FROM ALENDRONATE TO DENOSUMAB
    Roux, C.
    Brown, J. P.
    Kendler, D. L.
    Lillestol, M.
    Siddhanti, S.
    Man, H. S.
    Martin, J. San
    Bone, H. G.
    Benhamou, C. L.
    OSTEOPOROSIS INTERNATIONAL, 2009, 20 : 10 - 11
  • [40] Effects of Denosumab in Postmenopausal Women Transitioning from Alendronate Therapy in Comparison with Continued Alendronate
    Kendler, David L.
    Roux, Christian
    Benhamou, Claude Laurent
    Brown, Jacques P.
    Lillestol, Mike
    Siddhanti, Suresh
    Man, Hoi-Shen
    Martin, Javier San
    Bone, Henry G.
    JOURNAL OF RHEUMATOLOGY, 2009, 36 (11) : 2566 - 2567
12345